Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Autoimmune Inc.
Headquarters: Pasadena, CA, United States of America
Website: N/A
Year Founded: 1988
Status: Out of Business
BioCentury | Aug 20, 2020
Regulation
Pandemic could give advantage to newly approved MS latecomer ofatumumab
Novartis’ once-monthly anti-CD20 mAb is only auto-injectable MS drug targeting B cells
BioCentury | May 6, 2020
Emerging Company Profile
Ventus: A structural edge in innate immunity targets
Ventus debuts with $60M to uncover the underlying structural biology to drug innate immune pathways
BioCentury | Mar 12, 2020
Product Development
Targeted degradation gets another bump with Kymera’s $102M raise
BVF, Redmile lead Kymera’s series C to bring three targeted degraders to the clinic
BioCentury | Feb 21, 2020
Product Development
T regs are back - promising to do for autoimmunity what CAR Ts have done in cancer
A new generation of Treg cell therapies is springboarding off advances in CAR T cells and gene editing
BioCentury | Jan 14, 2020
Emerging Company Profile
Kyverna applies Tregs, CAR Ts to autoimmune diseases with $25M series A, Gilead deal
Cell Design Lab successor Kyverna aims to expand T cell therapies to autoimmune diseases
BioCentury | Jan 4, 2020
Emerging Company Profile
Rheos: applying immune cell reprogramming to autoimmunity
How Rheos is applying immunometabolism to autoimmunity to uncover personalized treatments
BioCentury | Mar 1, 2019
Translation in Brief
Targeting pathogenic Th17 cells
How two new autoimmune targets drive pathogenic Th17 activity
BioCentury | Nov 2, 2018
Targets & Mechanisms
Rethinking definitions of autoimmune disease
Why autoimmune diseases should be redefined by molecular pathway
Items per page:
1 - 10 of 77